Validated Colorimetric Assay of Clonidine Hydrochloride from Pharmaceutical Preparations

Andreia Corciova

doi:10.22037/ijpr.2016.1773

Validated Colorimetric Assay of Clonidine Hydrochloride from Pharmaceutical Preparations

authors:

Andreia Corciova

Department of Drugs Analysis, “Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Pharmacy, Iasi, Romania.

Warning: No corresponding author defined!

Iranian Journal of Pharmaceutical Research : IJPR: Vol.15, issue 1; 149-156

article type: Original Article

received: December , 2013

accepted: April , 2014

DOI: https://doi.org/10.22037/ijpr.2016.1773

how to cite: Corciova A. Validated Colorimetric Assay of Clonidine Hydrochloride from Pharmaceutical Preparations. Iran J Pharm Res. 2016;15(1):e125095. https://doi.org/10.22037/ijpr.2016.1773.

Abstract

Clonidine hydrochloride is an antihypertensive agent used for migraine prophylaxis, attention deficit hyperactivity disorder, menopausal flushing and Tourette syndrome. The quantity of the active substance in pharmaceutical preparations must be within specific limits, in agreement with the respective label claim. Therefore, the aim of this study was to establish the conditions for two spectrophotometric methods for clonidine determination, based on the formation of the ion pair complex between clonidine hydrochloride and thymol blue/bromophenol blue. A Jasco UV-Vis 530 spectrophotometer was used for the analysis and the maxim absorbance was measured at 418 nm/448 nm against blank solution. After validation, the methods were used for quantification of clonidine hydrochloride in two commercial samples (tablets). The recovery of active substance varies between 98.06 and 100.13 % without interferences from the excipients.

Keywords

Clonidine hydrochloride Quantitative assay UV-Vis spectrophotometry Ion-pair complexes Validation

Introduction

Clonidine (Figure 1), N-(2, 6-dichlorophenyl)-4, 5-dihydro-1H-imidazol-2-amine, is an imidazolinic derivative and exists as a mesomeric compound.

Chemical structure of clonidine hydrochloride

Figure 1

The substance is an α₂-adrenergic agonist. The decrease of blood pressure is mainly due to a central action, exerted on the reticular nucleus of the bulb, with consequent reduction of peripheral sympathetic and vagal cardio-inhibitory reflexes. As a result of the reduced peripheral sympathetic function, the levels of norepinephrine in plasma decrease. It also acts upon specific receptors for imidazoline structure - I₁ receptors that mediate the sympatho-inhibitory actions of imidazolines to lower the blood pressure.

Efficiency is highest 2-3 weeks after starting the treatment. It is used in hypertension - moderate and severe forms (commonly associated with diuretics, possibly with other antihypertensive), for prophylaxis of migraine and other forms of recurrent vascular headache and to treat menopausal flushing (1, 2). In an extended release formulation, FDA approved it for treatment of attention-deficit hyperactivity disorder (ADHD), from 2010 (3-5). Also, clonidine is used in Tourette syndrome (especially for tics) (6, 7).

It is contraindicated in patients with a history of depressive psychosis. It must be avoided or used with caution during pregnancy, severe cerebral arteriosclerosis, Raynaud's disease and obliterative thromboangiitis. Clonidine is contraindicated for drivers and those with other professions that require intense concentration and prolonged mental functions. It must not be administrated in association with alcohol and central depressants (barbiturates and other sedatives). Clonidine may present the next side effects: frequent dry mouth, constipation, drowsiness and sedation, relatively rare nausea, anorexia, sinus bradycardia, orthostatic hypotension, fluid retention (at baseline). Abrupt withdrawal may cause marked hypertension (rebound effect), headache, nervousness, tremor, gastrointestinal disorders (1, 2).

Clonidine hydrochloride is soluble in water and in anhydrous ethanol. The officialized analysis methods for clonidine hydrochloride are: a potentiometric titrimetric assay for drug determination according to European Pharmacopoeia and British Pharmacopoeia, and a spectrophotometric method based on the reaction with bromothymol blue for clonidine quantification in tablets, as described in British Pharmacopoeia (8, 9). The literature presents several methods for determination of clonidine hydrochloride from tablets, most of them being high performance liquid chromatography (HPLC) (10-13). There are a few colorimetric methods using reactions with sodium nitroprusside in presence of sodium hydroxide or with bromocresol green and supracen violet (14-17). Other methods used for clonidine hydrochloride analysis from tables are capillary electrophoresis (18), potentiometric assay (19), spectrophotometric titration in different non-aqueous solvents (20), derivative ratio spectrophotometry method and solvent extraction flow injection analysis using bromophenol blue (21).

Ion pair extraction has received considerable interest for quantitative determination of drugs because is a simple, cheap, sensitive and rapid method unlike other methods that are modern, expedient but involve complex instruments which may not be available in most laboratories. The aim of this study was to describe two methods for clonidine hydrochloride assay, based on the ion pair extraction technique, using thymol blue and bromophenol blue (22). In order to validate the proposed methods, we investigated the following validation parameters: linearity, limit of detection, limit of quantification, precision and accuracy in accordance with the bioanalytical method validation guidelines (23-26).

Experimental

Chemicals and reagents

Clonidine hydrochloride pure reference substance was supplied by Sigma Aldrich.
Clonidine hydrochloride tablets containing 0.15 mg drug were purchased from the pharmacy (two commercial products).
Bromophenol blue solution was prepared by dissolving 0.1 g bromophenol blue (Riedel de Haen) in 20 mL methanol and adding distilled water to 100 mL.
Thymol blue solution was prepared by dissolving 0.1 g thymol blue (Riedel de Haen) in 100 mL methanol.
Acetate buffer solution pH = 3 was prepared by dissolving 12 g sodium acetate in 50 mL distilled water, then adding 6 ml acetic acid and completing to 100 mL with distilled water.
Methanol p.a, Chloroform p.a., Acetic acid p.a., Sodium acetate p.a.(Chemical Company)

Methods used for ion-pair formation:

Method using bromophenol blue: 1 mL from each working solution was mixed into a separating funnel with 1 mL acetate buffer solution of pH = 3 and 1 mL of bromophenol blue solution. The complex was extracted for 5 min with two portions of 5 mL chloroform, passed through anhydrous sodium sulphate and completed with chloroform. After 30 min, the absorbance was measured at the wavelength of maximum absorption 448 nm, versus a blank solution prepared in similar conditions.
Method using thymol blue: 1 mL from each working solution was mixed into a separating funnel with 1 mL acetate buffer solution of pH = 3 and 2 mL of thymol blue solution. The complex was extracted for 5 min with two portion of 5 mL chloroform, passed through anhydrous sodium sulphate and completed with chloroform. After 20 min, the absorbance was measured at the wavelength of maximum absorption-418 nm, versus a blank solution prepared in similar conditions.

Preparation of stock standard solution100μg/mL:

10 mg of clonidine hydrochloride was dissolved in 3 mL methanol and completed to 100 mL with distilled water.

Working solutions

Containing from 0.5-7.5 μg/mL clonidine hydrochloride were obtained by diluting the stock solution with distilled water.

Preparation of sample solutions:

Twenty tablets from each sample product were weighed. Their average weight was calculated and then they were finely powdered in a glass mortar. Two quantities of powder, each equivalent to 30 mg clonidine hydrochloride, were weighed and transferred into a 100 mL volumetric flask. 10 mL methanol and 20 mL distilled water were added to both flasks and stirred for 10 min to dissolve the drug. The solutions were filtered through Whatman filter paper and completed to 100 mL with distilled water. The sample solutions were marked as Sample 1 and Sample 2. The procedure was continued as described on ion-pair formation procedure.

Instrument

A Jasco V 530 double beam UV-Vis spectrophotometer was used. All the measurements were made in 1.0 cm quartz cells at a scan speed of 1000 nm min^-1 and scan range of 400-600 nm, fixed slit width of 2 nm.

Results and Discussion

Optimization of variables

Selection of solvents for extraction of the complex

1 mL of working solution was mixed with 1 mL acetate buffer solution of pH = 3 and 1 mL of bromophenol blue solution/2 mL thymol blue solution. Then the complex was extracted with CCl₄, chloroform and dichloromethane and the absorbances were measured at 448 nm/418 nm.

Because the maximum absorbance was obtained with chloroform (Table 1), it was chosen as extraction solvent.

Table 1

Selection of solvents for extraction of the complex

Solvents	Absorbance ± SD
Solvents	Bromophenol blue	Thymol blue
CCl₄	-	-
Chloroform	1. 0896 ± 0.003	0.8796 ± 0.007
Dichloromethane	0.4315 ± 0.036	0.2673 ± 0.005

Selection of pH and reaction time

1 mL bromophenol blue solution/2 mL thymol blue solution was added to the 1 mL working solution and the pH was adjusted to pH = 3, pH = 4.6 and pH = 5. After extraction, the absorbances were recorded at different time intervals. The results are represented in Figure 2 and Figure 3.

Selection of pH dependence and reaction time for method with bromophenol blue solution.

Figure 2

Selection of pH dependence and reaction time for method with thymol blue solution.

Figure 3

As it can be seen, the optimal stabilities of the formed complexes were obtained at pH = 3 with both dyes and the optimum reaction time was 30 min for bromophenol blue solution method and 20 min for thymol blue solution method.

Selection of dye concentration and quantity

The influence of the concentration of dyes and the quantity used are presented in Table 2 and Table 3.

Table 2

Selection of dye concentration

Dyes	0.05%	0.1%	0.5%
Bromophenol blue solution	0.1955	0.6911	0.5425
Thymol blue solution	0.4825	0.5862	0.3602

Table 3

Selection of dye quantity

Dyes	0.5 mL	1 mL	1.5 mL	2 mL	2.5 mL
Bromophenol blue solution	0.2132	0.6763	0.6752	0.6743	0.6729
Thymol blue solution	-	0.5862	0.7108	0.8856	0.8662

The optimum concentration of the two dyes used was 0.1% and the quantity of dye was established at 1 mL for bromophenol blue solution and 2 mL for thymol blue solution.

Validation of methods

Linearity

Three determinations for each concentration were made and a mean value of the absorbances read at 448 nm/418 nm was calculated (Table 4). The calibration curves were obtained by plotting the mean values of the absorbances of clonidine hydrochloride vs clonidine hydrochloride concentrations (μg/mL) and are presented in Figure 4 and Figure 5.

Table 4

Absorbance values for linearity study

Statistical data	Method with bromophenol blue solution	Method with thymol blue solution
Pearson Coefficient (r²)	0.999	0.9995
Standard Error	0.012978	0.003889
Intercept	0.4628	0.6213
Slope	0.1245	0.0528
Limit of detection	0.039115	0.011721
Limit of quantification	0.11853	0.035519

Calibration curve for clonidine hydrochloride with bromophenol blue solution

Figure 4

Calibration curve for clonidine hydrochloride with thymol blue solution

Figure 5

Statistical data regarding clonidine hydrochloride determination are shown in Table 5.

Table 5

Statistical data regarding clonidine hydrochloride determination

Statistical data	Method with bromophenol blue solution	Method with thymol blue solution
Pearson Coefficient (r²)	0.999	0.9995
Standard Error	0.012978	0.003889
Intercept	0.4628	0.6213
Slope	0.1245	0.0528
Limit of detection	0.039115	0.011721
Limit of quantification	0.11853	0.035519

Repeatability (System precision)

For determination of repeatability, solutions at concentrations of 1.5 μg/mL in six replicates were used. The absorbances were measured and then the average, SD and % RSD were calculated. Table 6 shows the experimental data of the absorbances related to the precision of the system.

Table 6

Experimental data of the absorbances relating to the precision of the system

No	Absorbance
	Method with bromophenol blue solution	Method with thymol blue solution
1.	0.6759	0.7028
2.	0.6692	0.6999
3.	0.6649	0.6983
4.	0.6703	0.7058
5.	0.6732	0.711
6.	0.6697	0.7037
Average	0.6705	0.7035
SD	0.0037	0.0045
% RSD	0.5587	0.6420

Relative standard deviation (RSD) was found to be 0.5587% and 0.6420% respectively, which is lower than the maximum 2% proposed by the European standards, so the system is considered to be precise.

Method precision and accuracy

To investigate the method precision, solutions of three concentration levels were chosen and three determinations were made for each of them. Tables 7 and 8 present the calculated concentrations and the recovery of the methods in the same day, at different times (8.00 a.m., 12.00 a.m. and 16.00 p.m.) and in 3 consecutive days (day 1, 2 and 3).

Table 7

Calculated concentrations and the recovery of the method in the same day

Method with bromophenol blue solution
8.00 a.m.			12.00 a.m.			16.00 a.m.
Abs	Calc. conc.	% Recovery	Abs	Calc. conc.	% Recovery	Abs	Calc. conc.	% Recovery
0.6495	1.4995	99.97	0.6499	1.5028	100.18	0.6489	1.4947	99.65
0.6488	1.4939	99.59	0.6478	1.4859	99.06	0.6478	1.4859	99.06
0.6477	1.4851	99.00	0.65	1.5036	100.24	0.648	1.4875	99.17
0.7745	2.5036	100.14	0.7737	2.4971	99.88	0.7746	2.5044	100.17
0.7721	2.4843	99.37	0.7742	2.5012	100.04	0.7738	2.4979	99.91
0.7739	2.4987	99.95	0.7737	2.4971	99.88	0.7741	2.5004	100.01
1.0852	4.9991	99.98	1.0802	4.9590	99.18	1.0803	4.9598	99.19
1.0829	4.9807	99.61	1.0805	4.9614	99.22	1.081	4.9654	99.31
1.0859	5.0048	100.09	1.0811	4.9662	99.32	1.0839	4.9887	99.77
Average		99.75	Average		99.67	Average		99.58
SD		0.379	SD		0.468	SD		0.412
% RSD		0.380	% RSD		0.469	% RSD		0.414
Method with thymol blue solution
8.00 a.m.			12.00 a.m.			16.00 a.m.
Abs	Calc. conc.	% Recovery	Abs	Calc. conc.	% Recovery	Abs	Calc. conc.	% Recovery
0.6998	1.4867	99.11	0.701	1.5094	100.63	0.6999	1.4886	99.24
0.7001	1.4924	99.49	0.7009	1.5075	100.50	0.7012	1.5132	100.88
0.7011	1.5113	100.75	0.7009	1.5075	100.50	0.7	1.4905	99.36
0.7522	2.4791	99.16	0.7537	2.5075	100.30	0.7525	2.4848	99.39
0.754	2.5132	100.53	0.7529	2.4924	99.69	0.752	2.4753	99.01
0.7538	2.5094	100.37	0.7528	2.4905	99.62	0.7522	2.4791	99.16
0.8849	4.9924	99.84	0.8845	4.9848	99.69	0.8839	4.9734	99.46
0.8852	4.9981	99.96	0.8839	4.9734	99.46	0.8839	4.9734	99.46
0.8851	4.9962	99.92	0.8828	4.9526	99.05	0.886	5.0132	100.26
Average		99.90	Average		99.94	Average		99.58
SD		0.579	SD		0.556	SD		0.59
% RSD		0.580	% RSD		0.556	% RSD		0.60

Table 8

Recovery values of the method in three consecutive days

		% RSD		% RSD		% RSD
Method with bromophenol blue solution	Day 1	0.42	Day 2	0.56	Day 3	0.61
Method with thymol blue solution	Day 1	0.57	Day 2	0.65	Day 3	0.59

The mean recovery of the tests made in the same day for the method with bromophenol blue solution was in the range 99,00-100,24%, with SD = 0.379-0.468 and % RSD = 0.38-0.469 and for the method with thymol blue solution was in the range 99.01-100.88%, with SD = 0.556-0.59 and % RSD = 0.556-0.60.

The RSD values in 3 different days were in the range 0.42-0.61 for the bromophenol blue solution method and in the range 0.57-0.65 for thymol blue solution method.

As it can be seen the RSD values are lower than maximum 5% proposed by the European standards, therefore the method is accurate.

Application on tablets

The applicability of the two methods was demonstrated on two samples from pharmacy (Sample 1 and Sample 2), in 3 consecutive days, on 3 replicates each day. Table 9 presents the average of the 3 replicates of mg clonidine hydrochloride/tablet found and % recovery, considering that the declared concentration is 0.15 mg/tablet.

Table 9

Clonidine hydrochloride concentrations found in samples

	Method with bromophenol blue solution
	Sample 1		Sample 2
	mg found/tablet ± SD	%Recovery	mg found/tablet ± SD	%Recovery
Day 1	0.1490 ± 0.003	99.33	0.1471 ± 0.031	98.06
Day 2	0.1499 ± 0.012	99.93	0.1475 ± 0.007	98.33
Day 3	0.1502 ± 0.029	100.13	0.1486 ± 0.005	99.06
	Method with thymol blue solution
	Sample 1		Sample 2
	mg found/tablet ± SD	%Recovery	mg found/tablet ± SD	%Recovery
Day 1	0.1495 ± 0.026	99.66	0.1472 ± 0.008	98.13
Day 2	0.1503 ± 0.015	100.2	0.1477 ± 0.006	98.46
Day 3	0.1492 ± 0.079	99.46	0.1478 ± 0.017	98.53

The results obtained in the 3 days comply with the limits imposed by the regulations of Romanian Pharmacopoeia 10^th edition, Monography - Compressi [± 10%] (27) and the recoveries of active substance are in agreement with their respective label claim. Also, the results were compared with those obtained by the spectrophotometric method stipulated in European Pharmacopoeia and the differences were insignificant.

Conclusion

This paper establishes the conditions for clonidine hydrochloride assay by two spectrophotometric methods using bromophenol blue solution and thymol blue solution in acid medium. The methods are simple, cheap, accurate and precise and the results obtained showed that the proposed method for quantification of clonidine hydrochloride comply with validation parameters and can be applied successfully to the determination of substance in marketed formulations.

References

1.
Food and Drug Administration. Catapres (Clonidine Hydrochloride). Tables Prescribing Information. The Administration, USA. 2009:1-8.
2.
Karachalios GN. Hypertensive emergencies treated with oral clonidine. Eur J Clin Pharmacol. 1986;31:227-9. [PubMed ID: 3803420].
3.
Palumbo D, Sallee F, Pelham W Jr, Bukstein O, Daviss W, McDermott M. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:180-8. [PubMed ID: 18182963].
4.
Connor FD, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551-9. [PubMed ID: 10596256].
5.
6.
Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1991;48:324-8. [PubMed ID: 2009034].
7.
Schapiro NA. "Dude, you don't have Tourette's:" Tourette's syndrome, beyond the tics. Pediatr Nurs. 2002;3:243-53. [PubMed ID: 12087644].
8.
British Pharmacopoeia Commission Secretariat. British Pharmacopoeia volume III, Monography Clonidine Tablets. 2015.
9.
10.
Walters SM, Stonys DB. Determination of chlorthalidone and clonidine hydrochloride in tablets by HPLC. J Chromatogr Sci. 1983;21:43-5. [PubMed ID: 6833444].
11.
Yong-Gui MA, Zi-Ming L, Min M, Guo-Fang HE, Qiu-Lan W, Wen-Qing W. Determination of clonidine hydrochloride in compound clonidine hydrochloride tablets by RP-HPLC. Herald of Medicine. 2010;29:522-4.
12.
Wolf CE, Poklis A. A rapid HPLC procedure of analysis of analgesic pharmaceutical mixtures quality assurance and drug diversion testing. J Anal Toxicol. 2005;29:711-4. [PubMed ID: 16419405].
13.
Devanaboyina N, Kumar BC, Vijay B, Bhanu MA, Gayathri V. Liquid chromatography method development and validation for analysis of clonidine in pharmaceutical dosage. J Atom Mol. 2012;2:93-102.
14.
Tawakkol MS, Jado AI, Aboul-Enein HY. Colorimetric determination of clonidine. Arzneimittelforschung. 1981;31:1064-6. [PubMed ID: 7196753].
15.
Zivanov-Stakic D, Panic L, Agbaba G. Spectrophotometric determination of clonidine in dosage forms using bromocresol green. Farmaco. 1990;45:381-3. [PubMed ID: 2383349].
16.
Guimaraes SS, Sousa GD, Grangeiro S Jr, Castelo Branco DM, Albuquerque MM, Leal LB, Santana DP. Spectrophotometric determination of clonidine hydrochloride through the formation of ion-pair complex. Lat Am J Pharm. 2012;31:1222-5.
17.
Sastry CSP, Sailaja A, Rao TT, Krishna DM. Spectrophotometric determination of clonidine hydrochloride through the formation of ion-pair complex 3B. Indian Drugs. 1992;29:473-7.
18.
Sheng-Rain SU, Yun-Qiu YU. Simultaneous determination of clonidine hydrochloride hydrochlorothiazide as rutin in Zhenju tablet by capillary electrophoresis. J Chin Pharm Sci. 2005;14:173-5.
19.
Ganjali MR, Karimi A, Shahtaheri SJ, Norouzi P. Determination of clonidine by potentiometry using PVC membrane electrode. Int J Electrochem Sci. 2013;8:1999-2008.
20.
Sell E, Chmielewska A, Konieczna L. Spectrophotometric titration of the mixtures containing antihypertensive agents in non-aqueous differentiating solvents. Chem Anal. 2000;45:249-55.
21.
Haggag RS, Belal SF, Abdel-Aziz Shaalan R. Selective stability-indicating methods for the determination of clonidine hydrochloride and/or its related substance, 2, 6-dichloroaniline. J Food DrugAnal. 2011;19:174.
22.
Gölcü A, Yücesoy C. Colorimetric determination of amlodipine besylate in tablets. J Sci Eng Res. 2006;9:52-4.
23.
Narade S, Patil S, Surve S, Shete D, Pore Y. Development and validation of UV spectrophotometric method for the determination of diacerein in capsules. Digest J Nanomaterials Biostructures. 2010;5:113-8.
24.
Anandakumar K, Kannan K, Vetrichelvan T. Development and validation of emitricitabine and tenofovir disoproxil fumerate in pure and in fixed combination by UV spectrophotometry. Digest J Nanomaterials Biostructures. 2011;6:1085-90.
25.
Rouessac F, Rouessac A. Chemical Analysis: Modern Instrumental Methods and Techniques. John Willey and Sons LTD, Chichester. 2000:385-400.
26.
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2(R 1), Complementary Guideline on Methodology dated 06 November. ICH, London; 1996.
27.
Romanian Pharmacopoeia. Monography Compressi. . 10th ed. Editura Medicala, Bucuresti; 1993. p. 284-6.

comments